Fresenius SE & Co. KGaA
Investor Relations & Sustainability
+49 (0) 6172 608-2485
Fresenius continues to expect Group sales to grow organically with a compounded annual growth rate (CAGR) of 4% to 7% during 2020 to 2023. Group net income1,2 is projected to increase organically with a CAGR of 5% to 9% during 2020 to 2023. Fresenius expects its sales growth and efficiency improvement initiatives as well as Fresenius Kabi’s biosimilarsBiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved. business to drive an acceleration of Group earnings growth over that period. Small and medium-sized acquisitions are expected to contribute an incremental CAGR of approx. 1%-point to both sales and net income growth.
1 Net income attributable to shareholders of Fresenius SE & Co. KGaA
2 Before special item
|CAGR 2020 – 2023|
|Organic sales growth||4% to 7%|
|Organic net income growth1, 2||5% to 9%|
|1 Before special items|
|2 Net income attributable to shareholders of Fresenius SE & Co. KGaA|
COVID-19 will continue to impact Fresenius’ operations in 2021. Current burdens and constraints caused by COVID-19 are expected to recede only in H2/21. The expected improvement in the Group’s relevant business environment from H2/21 is heavily dependent on continuously increasing levels of vaccination coverage. These assumptions are subject to considerable uncertainty.
Fresenius closely monitors the development of COVID-19 case numbers, and the associated various containment measures being enacted in many of the Company’s relevant markets. The Group’s FY/21 guidance does not reflect any potential further containment measures that could have a significant and direct impact on the health care sector without any appropriate compensation.
|Targets 20211||Fiscal year 20202|
|Sales growth (in constant currency)||Low-to-mid single-digit percentage growth||€ 36,277 m|
|Net income3 growth (in constant currency)||At least broadly stable||€ 1,796 m|
|Dividend||Further increase intended||Proposal +5% per share|
|1 Including expected COVID-19 effects, before special items|
|2 Before special items, including COVID-19 effects|
|3 Net income attributable to shareholders of Fresenius SE & Co. KGaA|
Health care sector and markets
Sales and earnings by business segment